文献速递关节外科运动医学

解剖型全肩关节置换新技术对患者价值的评估

Assessing the Value to the Patient of New Technologies in Anatomic Total Shoulder Arthroplasty.
PubMed 文献 · J Bone Joint Surg Am · 2021-01-01

该综述回顾114篇报告解剖型全肩关节置换术前术后常用患者报告指标的文献,分析20年间新技术是否改善患者结局。分析未发现全肩关节置换结果在统计学或临床上改善的证据,也未发现任何单项技术与患者结局显著改善相关。需进一步研究记录这些新技术对盂肱关节炎患者的临床价值。

要点

  • 20年间解剖型全肩关节置换的患者报告结局未见统计学或临床显著改善。
  • 术前CT、三维规划、患者特异性器械、无柄/短柄肱骨组件及金属背衬/混合/增强肩胛盂组件均未显示与患者结局显著改善相关。
  • 证据等级为治疗性IV级,需进一步研究记录新技术对盂肱关节炎患者的临床价值。

核心结论

  • 分析未发现解剖型全肩关节置换结果在20年研究期间有统计学或临床改善的证据。
  • 也未发现任何单项新技术与患者结局显著改善相关。
  • 需进一步研究记录这些新技术对盂肱关节炎患者的临床价值。

研究设计与样本

  • 综述114篇报告解剖型全肩关节置换术前和术后常用患者报告指标值的文章。
  • 分析这些结果以确定在新技术可用的20年间患者结局是否改善。
  • 证据等级为治疗性IV级。

主要发现

  • 分析未识别出全肩关节置换结果在研究20年间有统计学或临床改善的证据。
  • 分析未识别出任何单项技术与患者结局显著改善相关的证据。

临床怎么用

  • 临床引入术前CT、三维规划、患者特异性器械、无柄/短柄肱骨组件及金属背衬/混合/增强肩胛盂组件等新技术时,应认识到其患者报告结局获益尚缺乏证据支持。

局限性

  • 证据等级为治疗性IV级。
  • 需额外研究记录这些新技术对盂肱关节炎患者的临床价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Publications regarding anatomic total shoulder arthroplasty (TSA) have consistently reported that they provide significant improvement for patients with glenohumeral arthritis. New TSA technologies that have been introduced with the goal of further improving these outcomes include preoperative computed tomography (CT) scans, 3-dimensional preoperative planning, patient-specific instrumentation, stemless and short-stemmed humeral components, as well as metal-backed, hybrid, and augmented glenoid components. The benefit of these new technologies in terms of patient-reported outcomes is unknown. METHODS: We reviewed 114 articles presenting preoperative and postoperative values for commonly used patient-reported metrics. The results were analyzed to determine whether patient outcomes have improved over the 20 years during which new technologies became available. RESULTS: The analysis did not identify evidence that the results of TSA were statistically or clinically improved over the 2 decades of study or that any of the individual technologies were associated with significant improvement in patient outcomes. CONCLUSIONS: Additional research is required to document the clinical value of these new technologies to patients with glenohumeral arthritis. LEVEL OF EVIDENCE: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Schiffman CJ, Prabhakar P, Hsu JE, et al. Assessing the Value to the Patient of New Technologies in Anatomic Total Shoulder Arthroplasty. J Bone Joint Surg Am. 2021. PMID: 33587515. doi:10.2106/JBJS.20.01853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。